Drug Channels

SEPTEMBER 25, 2024

ET on the following dates: April 4, 2025 June 20, 2025 December 12, 2025 (Drug Channels Outlook 2026) For 2025, we are offering a Corporate Pricing option that will allow larger organizations to register hundreds of colleagues for one fixed price. The three events are scheduled for 12:00 p.m. to 1:30 p.m.

Drugs 52

Drugs Marketing 52

Agency IQ

MARCH 25, 2024

ECHA flags 28 substances for evaluation over next three years This week, ECHA finalized its annual update to the Community Rolling Action Plan (CoRAP), listing 28 substances that will be assessed under the REACH Regulation’s substance evaluation procedure during the 2024-2026 period.

Compliance 40

Compliance Production Regulations 40

Agency IQ

JULY 22, 2024

According to that version of the plan, the actor and market surveillance modules would be complete as of Q4 2023, the certificates module by Q1 2024, the device and vigilance modules by the end of Q2 2024, and the CI/PS module estimated to be ready for Q3 2026. The announcement that the vigilance module is ready is projected for January 2026.

Regulations 40

Regulations Marketing Clinical Trials Trials 40

FDA Law Blog: Biosimilars

JUNE 26, 2023

September 1, 2023 will be the selection date for the 10 drugs that will be subject to “maximum fair price” ceilings under Medicare Part D starting in 2026. Chamber of Commerce makes all the arguments that the other plaintiffs have made, and also alleges that Congress has no power to levy the excise tax because it “compels” commerce.

Pharmaceuticals 59

Pharmaceuticals Drugs Research Government 59

The Pharma Data

SEPTEMBER 27, 2021

7.125% Notes due 2025 532457 AM0 3 0.750% due August 31, 2026 0.820% 15 bps $1,222.65 5.500% Notes due 2027 532457 AZ1 7 0.750% due August 31, 2026 0.820% 40 bps $1,226.23 3.100% Notes due 2027 532457 BP2 13 0.750% due August 31, 2026 0.820% 35 bps $1,100.66

Disease 52

Disease Marketing 52

FDA Law Blog: Biosimilars

OCTOBER 13, 2024

No rare pediatric disease vouchers could be awarded even to designated applications after September 30, 2026. After this date, without action by Congress, FDA’s authority to grant rare pediatric disease designations would expire, and no vouchers could be granted unless previously granted such a designation.

Disease 64

Disease FDA FDA Approval Government 64

Perficient: Drug Development

MAY 30, 2024

.” – Marybeth Wrabel How We’re Approaching Transformation, Modernization, and Mandates There’s plenty of discussion and investment happening already among insurers, as they address interoperability and prepare for a Prior Authorization mandate in 2026.

Regulations 88

Regulations Science Marketing 88

Perficient: Drug Development

OCTOBER 15, 2024

A recent study from IDC suggests that by 2026, 70% of financial institutions will have formalized data governance frameworks in place. With the rise of AI, machine learning, and real-time data analytics, banks will need to be even more diligent in how they manage and govern their data.

Government 52

Government Compliance Regulations Production 52

Perficient: Drug Development

DECEMBER 27, 2023

The effective date of the new rule is April 1, 2024, with key provisions taking effect on January 1, 2026, and January 1, 2027. Banks Additionally, the recent rule by the OCC, the Federal Reserve, and the FDIC strengthens and modernizes Community Reinvestment Act (CRA) regulations.

Compliance 52

Compliance Regulations Production 52

Perficient: Drug Development

AUGUST 22, 2023

According to Gartner’s 2022 Industry Cloud Survey , about 40% of IT leaders say they have started to adopt industry cloud platforms, with another 15% in pilots; another 15% are considering deployment by 2026. One of the ways healthcare and life sciences organizations are moving to the cloud is by adopting digital health platforms (DHP).

Science 98

Science Marketing Production 98

The Pharma Data

MARCH 31, 2023

This would support extension of the regulatory data protection to November 2026. If approved, Entresto will become available to children with a new age-appropriate formulation to enable accurate and convenient administration for these patients and their caregivers.

Hospitals 75

Hospitals Trials Treatment Clinical Trials 75

FDA Law Blog: Biosimilars

OCTOBER 12, 2023

Priority is given to Suitability Petitions that could mitigate or resolve a drug shortage; address a public health emergency declared by HHS; mitigate waste by way of new strengths for parenteral products; or subject to special review under the President’s Emergency Plan for Aids Relief.

FDA 59

FDA Drugs Production 59

The Pharma Data

OCTOBER 31, 2020

billion USD by 2026 at a CAGR of 11.5%. With the IND approval in place, we are ready and eager to extend the clinical study of TG-1000 to the U.S. in the near future.” ” According to Global Data, the global market for influenza antivirals reached 2.34 billion USD in 2019 and is estimated to reach 5.03

FDA Approval 52

FDA Approval FDA Clinical Development Virus 52

The Pharma Data

SEPTEMBER 7, 2021

0.750% due August 31, 2026. 0.750% due August 31, 2026. 0.750% due August 31, 2026. 0.750% due August 31, 2026. 3.950% Notes due 2049. 532457 BT4. 1,500,000,000. 2.375% due May 15, 2051. 7.125% Notes due 2025. 532457 AM0. 229,692,000. 6.770% Notes due 2036. 532457 AP3. 174,445,000. 1.250% due August 15, 2031. 532457 BC1.

Licensing 52

Licensing Licensing Marketing 52

The Pharma Data

MAY 2, 2023

Starting in 2026, this facility will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for use in clinical trial phases. This step is crucial for Boehringer Ingelheim to rapidly advance new drug candidates from the company’s vast research pipeline to clinical trials and ultimately to market approval.

Small Molecule 40

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 40

Agency IQ

JULY 22, 2024

EPA’s regulatory agenda for Spring 2024 Agenda Stage of Rulemaking Title Estimated Publication Former Estimated Date First on Agenda Proposed Rule Stage Removal of Affirmative Defense Provisions from Specified CAA Section 111 and 112 Regulations July 2024 Spring 2024 Final Rule Stage Standards of Performance for New, Reconstructed, and Modified Sources (..)

Regulations 40

Regulations Production Engineering International 40

The Pharma Data

JUNE 28, 2023

3 The Company is on track to reduce greenhouse gas emissions (GHGs) from its operations and fleet by 98% by 2026 * and halve its entire value chain footprint by 2030, on the way to a 90% absolute emissions reduction and becoming science-based net zero by 2045 ** at the latest.

Science 40

Science Government 40

LifeSciVC

APRIL 2, 2024

We have milestones on the horizon, and we want investors to stay close to the Sionna story even if we don’t need capital until 2026. As an example of the continued engagement, we headed to the TD Cowen healthcare conference in early March before the ink was dry on the Series C closing.

Science 68

Science Small Molecule International Clinical Development 68

The Pharma Data

MARCH 31, 2022

million patients, provided with essential medicines by the global health unit, for the treatment of non-communicable diseases in 40 of the world’s poorest countries, between 2022 and 2026. The coupon amounts are linked to the achievement of a sustainability performance target defined as the cumulative number of patients, being at least 1.5

Treatment 52

Treatment Government Vaccine Disease 52

The Pharma Data

DECEMBER 8, 2020

Ionis projects having the opportunity to launch six or more new products through 2026, with each being ready for launch in a close window, ranging from 18 to 24 months between each new product launch. The expectation is that the implementation of this strategy will drive double-digit revenue growth and substantial earnings growth. .

RNA 52

RNA Pharmaceuticals Disease Production 52

Agency IQ

MAY 28, 2024

Transitional conditions are given in Article 25 , which set January 12, 2026 as the deadline for member states to ensure compliance with the parametric values for bisphenol A, chlorate, chlorite, haloacetic acids, microcystin-LR, uranium, and total and sum values of per- and polyfluoroalkyl substances (PFAS).

Compliance 40

Compliance Production Pharmaceuticals Treatment 40

FDA Law Blog: Biosimilars

OCTOBER 4, 2023

Note that Astellas withdrew its lawsuit after none of its drugs were selected for price reduction in 2026—potentially because that fact cut against its argument for standing. Harm The Court reviewed the parties’ arguments on “irreparable harm to Plaintiffs.”

Pharmaceuticals 59

Pharmaceuticals Drugs Government Regulations 59

Drug Target Review

JANUARY 4, 2024

Then it’s on to dosing and administration studies in animals, pivotal toxicology studies, and, following a successful funding round, first-in-human studies in 2026. We’ve made great progress to date and have every faith that the program will continue to progress with remarkable promise.

Therapies 98

Therapies Small Molecule Production Disease 98

The Pharma Data

APRIL 14, 2021

The five-year project will see the site fully operational in Q1 2026 once all qualifications and validations of the first manufactured vaccine have been completed. The project is currently entering its design phase with construction expected to begin in Q3 2021.

Vaccine 52

Vaccine Production Disease International 52

Agency IQ

MARCH 29, 2024

UCMR5 targets 29 different PFAS and lithium for testing between 2022 and 2026. UCMRs are released every 5 years, with the most recent UCMR, UCMR 5 , released on December 27, 2021.

Regulations 40

Regulations Compliance Production Treatment 40

The Pharma Data

MAY 15, 2023

Work is set to begin this year, with full operations provisionally planned for late 2026. In addition, Sandoz recently signed a Memorandum of Understanding to build a new biologics production plant in Slovenia – an expected investment of at least USD 400 million to support increasing global demand for biosimilar medicines.

Biosimilars 40

Biosimilars Production Government Clinical Trials 40

Advarra

AUGUST 8, 2024

While some of the AI Act’s compliance dates are set for August 2024, the full Act will be enforced in March 2026. Unacceptable risk AI systems are banned outright, while high-risk systems must comply with stringent requirements, including transparency, data governance, registration with the central competent authorities, and human oversight.

Clinical Research 52

Clinical Research Research Clinical Trials Compliance 52

National Institute on Drug Abuse: Nora's Blog

DECEMBER 14, 2022

Greater involvement of people with lived experience in all aspects of research is one of the themes of NIDA’s 2022-2026 Strategic Plan. All projects will have a community advisory board and/or people with lived experience will have paid positions to support the research.

Research 52

Research Treatment Disease Drugs 52

Drug Target Review

JULY 4, 2023

The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026. 1 Regulators invest significant consideration balancing quality-of-life measures with overall survival when assessing novel oncology treatments.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

The Pharma Data

JUNE 26, 2021

Those taking up this offer will be required to hold the Shares or the corresponding FCPE units for a period of approximately five years, i.e. until 31 May 2026, except upon the occurrence of an early release event provided for under Article R. The voting rights attached to the subscribed Shares will be exercised directly by the employees.

Regulations 52

Regulations Marketing 52

The Pharma Data

APRIL 15, 2022

New GSK reaffirms its full-year 2022 guidance, the medium-term outlook for 2021-2026 of more than 5% sales and 10% adjusted operating profit CAGR* at CER**, and long-term sales ambition.

Treatment 52

Treatment FDA Approval Trials Clinical Trials 52

National Institute on Drug Abuse: Nora's Blog

SEPTEMBER 27, 2022

One of the cross-cutting themes of NIDA’s new FY 2022-2026 Strategic Plan is greater involvement of people with lived experience in research design, and the science of recovery supports is emblematic of how successful that mindset can be.

Research 52

Research Treatment Science Trials 52

The Pharma Data

APRIL 6, 2022

“With our portfolio of in-market medicines and up to 20 major pipeline assets that could be approved by 2026, Novartis is in a strong position to deliver above-peer-median sales and margin growth in the mid- and long-term.” ” Integrating Pharmaceuticals and Oncology business units.

International 52

International Pharmaceuticals Drug Development Marketing 52

The Pharma Data

JANUARY 18, 2021

Under this program, companies are eligible to receive a priority review voucher following approval of a product with rare pediatric disease designation if the marketing application submitted for the product satisfies certain conditions, including approval prior to September 30, 2026 unless changed by legislation.

Therapies 52

Therapies Disease Treatment FDA 52

Agency IQ

JANUARY 4, 2024

The current approved objectives cover the years 2023 – 2026, laying out the regulator’s approach to surveillance, international cooperation, support of innovation, and how its activities will be funded. The TPA requires the Swissmedic Agency Council to create strategic objectives for approval by the Federal Council.

Marketing 40

Marketing Regulations Clinical Trials International 40

Agency IQ

JULY 22, 2024

Analysis and next steps The roadmap is expected to be finalized sometime in late 2025, or early 2026 , according to the presentation. An “implementation phase that implements the planned actions” will follow its release.

Animal Testing 40

Animal Testing Regulations Production Research 40

Agency IQ

MAY 10, 2024

As of January 1, 2026, the law will implement a variety of new prohibitions on intentionally added PFAS in products, including in cookware, cosmetics, cleaning products, and most textiles. Recently enacted legislation Maine: On April 16, 2024, Maine Governor JANET MILLS approved L.D.

Packaging 40

Packaging Regulations Production Compliance 40